Dyne Therapeutics, Inc. (DYN) fair value analysis
Nasdaq · Updated 2026-10-19
DYN price how computed
Valuation status
No fair-value estimate yetDYN has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for DYN yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $14.25
- Sector
- Healthcare
- 12-month range
- $14.25–$26.78
- Market cap
- $3.11B
- From 52-week high
- -46.8%
- Shares outstanding
- 218M
- Rank in Healthcare by quality score
- #236 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Dyne Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel treatments for serious neuromuscular diseases. The company operates in the United States and conducts research and development activities in the healthcare sector.
DYN currently ranks #236 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $3.11B
- P/E (trailing)
- n/m
- EPS (TTM)
- $-3.30
- Debt / equity
- 0.03
- Shares outstanding
- 218M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 26 · oversold
- 50-day average
- $20.53
- 200-day average
- $19.41
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▼ miss (-45.9%)
2026-03 ▲ beat (+6.4%)
2025-12 ▲ beat (+5.5%)
2025-09 ▲ beat (+6.2%)
2025-06 ▼ miss (-4.3%)
2025-03 ▼ miss (-25.0%)
2024-12 ▲ beat (+3.5%)
2024-09 ▼ miss (-35.2%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 16 buy · 1 hold · 0 sell (17 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $35.7
- Target vs last price
- +150.5%
What our data shows for DYN
- Shares are trading in the lower third of their 12-month price range of $14.25–$26.78.
- The 14-day relative strength index sits at an oversold 26.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- DYN's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the DYN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for DYN showed a shift this week as the RSI zone moved from neutral to oversold. The current valuation verdict remains awaiting full valuation. This technical change reflects recent price movement in the Healthcare sector stock.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for DYN in the Healthcare sector showed a shift this week, with the RSI zone moving from oversold to neutral. The current valuation verdict remains awaiting full valuation. This change suggests a potential stabilization in the stock's momentum following its previously oversold condition.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is DYN stock undervalued?
TickrTrends has no fair-value estimate for DYN yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is DYN's TickrTrends verdict?
DYN is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does DYN compare to other Healthcare stocks?
DYN ranks #236 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is DYN overbought or oversold?
DYN's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does DYN report earnings next?
DYN's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does DYN usually beat earnings estimates?
Over its last 8 reported quarters DYN beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about DYN?
Of 17 analysts covering DYN, 16 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $35.7 (+150.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.